A preliminary study revealed pancreatic hyperplasia to be present in 29 per cent of 100 consecutive necropsies. Malignant neoplasms coexisted with hyperplasia of islets in 14 (48.3 per cent) of the 29 cases. On the basis of the results of this study, the islets of Langerhans in microscopic sections of pancreas from 20 cases of accidental death (normal controls), 10 cases of extrapancreatic lymphoma, and 12 cases of extrapancreatic sarcoma were quantitatively studied. Significant hyperplasia of the islets was present in both categories of neoplastic disease when compared with the islets in the control group. The assessment of hyperplasia of pancreatic islets was neither difficult nor complex when the observer assigned the proper significance to the presence of an increased percentage of large islets. The method for determining hyperplasia of islets and the significance of its presence are discussed.
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A preliminary study revealed pancreatic hyperplasia to be present in 29 per cent of 100 consecutive necropsies. Malignant neoplasms coexisted with hyperplasia of islets in 14 (48.3 per cent) of the 29 cases. On the basis of the results of this study, the islets of Langerhans in microscopic sections of pancreas from 20 cases of accidental death (normal controls), 10 cases of extrapancreatic lymphoma, and 12 cases of extrapancreatic sarcoma were quantitatively studied. Significant hyperplasia of the islets was present in both categories of neoplastic disease when compared with the islets in the control group. The assessment of hyperplasia of pancreatic islets was neither difficult nor complex when the observer assigned the proper significance to the presence of an increased percentage of large islets. The method for determining hyperplasia of islets and the significance of its presence are discussed. ( Only the measurements of islets greater than 115 p in diameter, a figure below the average diameter of an islet,Jas were recorded since islets much smaller than this might not be identified.
Data from the control series revealed that islets greater than 192 ,.I in their longest diameter were large. The percentage of large islets in each case was then calculated from the ratio: 
RESULTS
Preliminary Study: Definite hyperplasia of pancreatic islets was found in material from 29 of the 100 consecutive necropsies examined in the preliminary control group. In 14 of these 29 cases (48.3 per cent) extrapancreatic malignant neoplasms were also present. In the absence of coexisting diabetes mellitus or interstitial pancreatitis, hyperplasia of islets was rarely encountered in patients who died from such chronic illnesses as arteriosclerotic heart disease or chronic renal disease.
Quantitatirje Study. Table 1 presents the important data relevant to the control group of 20 patients who were victims of accidental death. The percentage of large islets ranged from 13.0 to 46.9 with a mean of 26.9. An analysis of the data revealed no correlation between the age or weight of the patient, weight of the pancreas, or percentage of large pancreatic islets. Figure  1 is a photomicrograph of a representative pancreatic islet of average size from a case of accidental death.
The group of extrapancreatic lymphomas included 10 patients. The important details and the percentage of large islets in each case are listed in table 2. The range of percentage of large islets was from 15.4 to 59.5 with a mean of 40.1. Statistical analysis of the data from table 1 (normal controls) and table 2 indicated the difference in the percentages of large islets to be significant (p < 0.005).* Figure 2 is a photomicrograph illustrating a hyperplastic pancreatic islet from a case of extrapancreatic lymphoma. Table 3 lists the 12 cases of extrapancreatic sarcomas. The percentage of large islets in this group ranged from 22.3 to 45.7 with a mean of 34.2. Statistical analysis of the data from table 1 (normal controls) and table 3 indicated the difference in the percentages of large islets to be significant (p < 0.01).
The frequency distribution of the percentage of large islets for each of the 3 groups of patients is presented in figure 3 . In 11 of the 20 cases of accidental death in the control group, the large islets comprised greater than 25 per cent of the total number of recorded islets. In 9 of the 10 cases in the extrapancreatic lymphoma group and in 11 of the 12 cases in the extrapan-"Normal approximation of the Rank-Sum test. slower. They suggested that the defect in carbohydrate metabolism reflected alterations in the metabolism of host tissue associated with the presence of the neoplastic process and was probably not attributable to the carbohydrate metabolism of the tumor. Indeed an hypothesis could be formulated with some justification that neoplasms may produce an anti-insulin metabolite capable of inactivating to some extent the peripheral utilization of glucose by the host, thereby diverting glucose to the neoplasm. Since insulin may not be required for glucose utilization by the neoplastic cells, the neoplasm would be teleologically benefited by such circumstances. The diabetic type glucose tolerance test in patients with neoplastic disease could also be a result of such an anti-insulin factor. Such a chain of events could account for the hyperplasia of the pancreatic islets in response to the increased demand by the host tissue for insulinogenesis.
HYPERPLASIA OF PANCREATIC ISLETS
Of paramount importance in substantiating these speculations is the differential staining of the islet cells. This might help to determine the functional activity of these hyperplastic islets. Such a staining procedure, however, requires special technics that could not be performed on the microscopic slides utilized in this study.
The pancreatic islets can be linked to metabolism and tissue growth in yet another fashion. Glucagon and insulin have both been incriminated as factors in growth promotion. Salter and Best14 reported that insulin promoted growth 
